Year Published
- 2008 (3) Apply 2008 filter
- (-) Remove 2009 filter 2009
- 2010 (10) Apply 2010 filter
- 2011 (9) Apply 2011 filter
- 2012 (4) Apply 2012 filter
- 2013 (1) Apply 2013 filter
- 2014 (3) Apply 2014 filter
- 2015 (3) Apply 2015 filter
- 2016 (13) Apply 2016 filter
- 2017 (8) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (1) Apply 2020 filter
- 2021 (0)
Research Topics
Populations
- Countries/Governments (1) Apply Countries/Governments filter
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (3) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (3) Apply Research Brief filter
Geography
- East Africa Region and Selected Countries (1) Apply East Africa Region and Selected Countries filter
- Global (1) Apply Global filter
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
Current search
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove Research & Development filter Research & Development
- (-) Remove 2009 filter 2009
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
In this brief, we report on measures of economic growth, poverty and agricultural activity in Ethiopia. For each category of measure, we first describe different measurement approaches and present available time series data on selected indicators. We then use data from the sources listed below to discuss associations within and between these categories between 1994 and 2017.
This report provides a general overview of trends in public and private agricultural research and development (R&D) funding and expenditures in Sub-Saharan Africa (SSA). The request is divided into two sections, covering public funding and private funding. Within each section, relevant data is presented on historical funding patterns, the types of research conducted, and which countries within SSA are financing R&D at the highest level. We find that the majority of growth in African public agricultural research funding took place in the 1960s, when real public spending on agricultural research increased 6% a year. From 1971 to 2000 annual growth averaged 1.4% a year. Public financing of agricultural R&D experienced a moderate shift in the 1990s from bilateral and multilateral donor funding to domestic government financing. The shift varied by country, but donor funding dropped for all SSA countries an average of 10%. Private research and development funding is heavily concentrated in developed countries with the United States and Japan the two biggest spenders. Within SSA, private R&D expenditures comprise 2% of all R&D spending. The main private actors in SSA are companies based in South Africa and Nigeria. The private sector is focused on research areas that involve marketable inputs, such as chemicals, seeds, and machines/
This report present a thorough review of relevant literature regarding labor constraints currently being faced in Sub-Saharan Africa (SSA). The review focuses on the impacts of labor supply issues, particularly as they relate to the use of new technology and management techniques, off farm labor migration, and the impacts of HIV/AIDS. The review is provides a basic breakdown of the different kinds of agricultural labor in SSA, before presenting the evidence on the causes and impact of agricultural labor constraints. Though labor constraints can be relevant on both the demand and supply side, especially for certain groups such as women and youth, our review follows the literature by focusing on the supply side issues. The literature reviewed was written between 1990 and 2008, and includes a combination of reports from government organizations and highly cited journal articles.
This brief presents an in depth analysis of the FAO’s methodology behind their calculations for hunger. The analysis includes a review of the key assumptions made by the FAO in their calculations, critiques of their methodology, and recommendations for future research. The critiques include opinions from the literature on the subject as well as from the authors of the request.
This brief presents an initial examination of the possibility of using Disability Adjusted Life Years (DALYs) as a way to evaluate agricultural interventions. We review DALYs, their formulation, and the data necessary to compute values. A review of relevant literature suggests that to use DALYs as an evaluative tool, an agricultural intervention must be tied to a specific disease, and from there, impacts on DALYs can be assessed.